Positive News SentimentPositive NewsNASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $5.91 +0.05 (+0.85%) (As of 02:43 PM ET) Add Compare Share Share Today's Range$5.62▼$5.9750-Day Range$5.33▼$8.3652-Week Range$3.65▼$8.44Volume73,485 shsAverage Volume166,844 shsMarket Capitalization$366.63 millionP/E Ratio53.73Dividend YieldN/APrice Target$8.39 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get biote alerts: Email Address biote MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.9% Upside$8.39 Price TargetShort InterestBearish3.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$86,116 Sold Last QuarterProj. Earnings Growth9.62%From $0.52 to $0.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.33 out of 5 starsMedical Sector304th out of 927 stocksMedicinals & Botanicals Industry2nd out of 12 stocks 3.5 Analyst's Opinion Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coveragebiote has received no research coverage in the past 90 days.Read more about biote's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.93% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in biote has recently increased by 1.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTMD. Previous Next 2.7 News and Social Media Coverage News Sentimentbiote has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for biote this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biote insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,116.00 in company stock.Percentage Held by Insiders13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for biote are expected to grow by 9.62% in the coming year, from $0.52 to $0.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 53.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.74.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 53.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.16.Read more about biote's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. About biote Stock (NASDAQ:BTMD)biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More BTMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTMD Stock News HeadlinesAugust 10, 2024 | seekingalpha.combiote Corp. (BTMD) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comRoth MKM Keeps Their Buy Rating on biote (BTMD)September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 9, 2024 | finance.yahoo.comBiote Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | markets.businessinsider.comHere's what to expect from biote A's earningsJuly 25, 2024 | finance.yahoo.comBiote Schedules Second Quarter 2024 Financial Results Release and Conference CallJune 20, 2024 | businesswire.comBiote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout SharesMay 9, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q1 2024 Earnings Call TranscriptSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 7, 2024 | msn.comBTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | businesswire.comBiote Reports First Quarter 2024 Financial ResultsMay 7, 2024 | seekingalpha.comEsperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlookApril 29, 2024 | finance.yahoo.comBiote Announces Definitive Settlement with FounderApril 23, 2024 | businesswire.comBiote Schedules First Quarter 2024 Financial Results Release and Conference CallMarch 25, 2024 | msn.comEsperion stock jumps 18% in wake of FDA label expansionsMarch 18, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial ProspectsMarch 14, 2024 | marketwatch.comBiote Soars 22% With Expected Acceleration in 2H 2024 SalesMarch 13, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q4 2023 Earnings Call TranscriptSee More Headlines Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/16/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CUSIPN/A CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.39 High Stock Price Target$9.00 Low Stock Price Target$6.55 Potential Upside/Downside+41.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio53.73 Forward P/E Ratio11.37 P/E GrowthN/ANet Income$3.32 million Net Margins3.67% Pretax Margin10.27% Return on Equity-20.92% Return on Assets10.29% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio0.92 Sales & Book Value Annual Sales$187.23 million Price / Sales1.96 Cash Flow$0.49 per share Price / Cash Flow11.99 Book Value($0.58) per share Price / Book-10.19Miscellaneous Outstanding Shares62,036,000Free Float53,413,000Market Cap$366.63 million OptionableNot Optionable Beta0.94 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Marc D. Beer (Age 59)Executive Chairman Comp: $470.18kMs. Teresa S. Weber (Age 71)CEO & Director Comp: $1.06MMs. Mary Elizabeth Conlon (Age 43)VP of Business Development, General Counsel & Corporate Secretary Comp: $552.36kMs. Mary J. Puncochar (Age 60)Head of Strategic Sales & Business Analytics Comp: $465.47kMr. Robert C. Peterson (Age 47)Chief Financial Officer Mr. John J. Olsen (Age 67)Chief Information Officer Mr. James Elliott Gibbs IIChief People OfficerMr. Richard Kevin Key (Age 53)Chief Digital Officer Mr. Jade Beutler (Age 61)Head of Nutraceuticals Dr. Cory Rice D.O.Chief Clinical Advisor & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsAdTheorentNASDAQ:ADTHDecarbonization Plus Acquisition Co. IVNASDAQ:DCRDOPAL FuelsNASDAQ:OPALNurix TherapeuticsNASDAQ:NRIXRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 11,271 shares on 8/15/2024Ownership: 0.018%Dimensional Fund Advisors LPBought 600,956 shares on 8/9/2024Ownership: 1.064%Renaissance Technologies LLCBought 138,200 shares on 8/9/2024Ownership: 0.311%GDS Wealth ManagementBought 57,789 shares on 8/9/2024Ownership: 0.093%WINTON GROUP LtdBought 3,124 shares on 8/9/2024Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $4.94 at the beginning of the year. Since then, BTMD shares have increased by 19.6% and is now trading at $5.91. View the best growth stocks for 2024 here. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) announced its earnings results on Thursday, August, 8th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm earned $49.17 million during the quarter, compared to analysts' expectations of $50.40 million. biote had a negative trailing twelve-month return on equity of 20.92% and a net margin of 3.67%. Who are biote's major shareholders? biote's top institutional shareholders include Dimensional Fund Advisors LP (1.06%), Renaissance Technologies LLC (0.31%), Skylands Capital LLC (0.26%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Roystone Capital Management Lp, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTMD) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
